Equities research analysts expect Qiagen NV (NASDAQ:QGEN) to announce earnings of $0.34 per share for the current quarter, according to Zacks. Two analysts have provided estimates for Qiagen’s earnings. The lowest EPS estimate is $0.33 and the highest is $0.35. Qiagen reported earnings of $0.32 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 6.3%. The business is expected to issue its next quarterly earnings results on Monday, November 5th.

On average, analysts expect that Qiagen will report full-year earnings of $1.33 per share for the current year, with EPS estimates ranging from $1.31 to $1.35. For the next year, analysts expect that the company will post earnings of $1.49 per share, with EPS estimates ranging from $1.45 to $1.58. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Qiagen.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings results on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.01. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The business had revenue of $377.20 million during the quarter, compared to analyst estimates of $376.89 million.

A number of research analysts have recently weighed in on the company. Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Monday, September 17th. BidaskClub lowered Qiagen from a “hold” rating to a “sell” rating in a research report on Thursday, September 13th. Barclays restated a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research report on Thursday, September 6th. Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. Finally, Deutsche Bank restated a “buy” rating on shares of Qiagen in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $38.33.

Shares of QGEN stock opened at $37.44 on Friday. The company has a quick ratio of 4.59, a current ratio of 5.07 and a debt-to-equity ratio of 0.69. Qiagen has a 52-week low of $30.20 and a 52-week high of $39.45.

Institutional investors have recently modified their holdings of the company. RTW Investments LP purchased a new position in Qiagen in the second quarter worth about $19,143,000. Swiss National Bank grew its position in Qiagen by 4.0% in the second quarter. Swiss National Bank now owns 1,076,264 shares of the company’s stock worth $39,095,000 after acquiring an additional 41,298 shares in the last quarter. M&T Bank Corp purchased a new position in Qiagen in the first quarter worth about $207,000. Strs Ohio purchased a new position in Qiagen in the second quarter worth about $394,000. Finally, Canada Pension Plan Investment Board grew its position in Qiagen by 84.4% in the second quarter. Canada Pension Plan Investment Board now owns 293,207 shares of the company’s stock worth $10,681,000 after acquiring an additional 134,171 shares in the last quarter. Hedge funds and other institutional investors own 62.23% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.